<DOC>
	<DOCNO>NCT02739984</DOCNO>
	<brief_summary>The purpose study evaluate effect 12 week subcutaneous evolocumab take monthly compare subcutaneous placebo take monthly low density lipoprotein cholesterol ( LDL-C ) subject type 2 diabetes mellitus high blood cholesterol maximally tolerate oral dose statin least moderate-intensity .</brief_summary>
	<brief_title>A Study Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia</brief_title>
	<detailed_description>This study enroll adult subject ( great equal 18 year age ) type 2 diabetes mellitus elevate LDL-C non-HDL-C level stable , maximally tolerate statin dose least moderate-intensity signing informed consent ; statin therapy must remain unchanged screen remainder study . Subjects must hemoglobin A1c ( HbA1c ) &lt; 10 % , must receive pharmacologic treatment diabetes mellitus great equal 6 month prior screen , stable diabetes therapy prior randomization investigational product ( IP ) expect change throughout duration study participation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female ≥18 year , Type 2 Diabetes Mellitus , Hemoglobin A1c &lt; 10 % , Stable Diabetes Therapy , Must maximally tolerate dose statin least moderate Intensity , Fasting triglycerides ≤ 600 mg/dL , Not LDLC NonHDLC goal . Moderate severe renal dysfunction , Uncontrolled hypertension , Persistent active liver disease hepatic dysfunction , Has take cholesterylester transfer protein inhibitor last 12 month , Myocardial infarction , unstable angina , percutaneous coronary intervention , coronary artery bypass graft stroke within 3 month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>high blood cholesterol</keyword>
	<keyword>hypercholesterolemia</keyword>
	<keyword>mixed dyslipidemia</keyword>
	<keyword>high cholesterol</keyword>
	<keyword>statin intolerant</keyword>
</DOC>